Bayer (BAYN) Given a €140.00 Price Target at Baader Bank
Baader Bank set a €140.00 ($166.67) price objective on Bayer (FRA:BAYN) in a research report sent to investors on Thursday morning. The brokerage currently has a buy rating on the healthcare company’s stock.
Several other research analysts have also recently weighed in on the company. Commerzbank set a €124.00 ($147.62) target price on Bayer and gave the company a buy rating in a research note on Wednesday, November 15th. J P Morgan Chase & Co reaffirmed a buy rating on shares of Bayer in a research note on Wednesday, September 13th. Barclays set a €105.00 ($125.00) target price on Bayer and gave the company a sell rating in a research note on Friday, November 17th. Berenberg Bank set a €124.00 ($147.62) target price on Bayer and gave the company a neutral rating in a research note on Friday, November 3rd. Finally, UBS set a €125.00 ($148.81) target price on Bayer and gave the company a buy rating in a research note on Monday, November 6th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have given a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of €122.19 ($145.46).
Shares of Bayer (BAYN) traded up €0.10 ($0.12) during mid-day trading on Thursday, reaching €106.50 ($126.79). The company had a trading volume of 6,184,479 shares. Bayer has a fifty-two week low of €95.48 ($113.67) and a fifty-two week high of €123.82 ($147.40).
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Stock Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related stocks with our FREE daily email newsletter.